Pacira | PCRX - Operating Profit

Stock Price
22.64
Daily Change
-0.89 -3.78%
Monthly
-5.11%
Yearly
-12.45%
Q2 Forecast
22.18

Pacira reported $4.62M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Assertio Holdings USD -3.05M 569K Sep/2024
Astellas Pharma JPY 48.57B 85.97B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 6.62B 1.03B Mar/2026
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026
Xeris Pharmaceuticals USD 16.77M 10.04M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024
Zoetis USD 865M 30M Mar/2026